Skip to main content

Drug Interactions between belimumab and Jaypirca

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

belimumab pirtobrutinib

Applies to: belimumab and Jaypirca (pirtobrutinib)

Consumer information for this interaction is not currently available.

MONITOR: Concomitant use of belimumab and biologic therapies, including B-cell targeted therapies with immunosuppressant effects may lead to an increase in the rate of severe adverse events and serious infections. In a double-blind, randomized, placebo-controlled, phase 3 trial in adults with systemic lupus erythematosus (SLE) receiving belimumab, the addition of rituximab was associated with serious adverse events in 22.2% and serious infections in 9% of patients, compared to 13.9% and 2.8% of patients, respectively, in the placebo add-on group. Clinical data for other B-cell targeted therapies are unavailable.

MANAGEMENT: According to the manufacturer of belimumab, available data do not support the coadministration of belimumab with rituximab in patients with SLE. Caution and monitoring for adverse reactions, particularly infections, is advised if concomitant use of belimumab with other biologic therapies with immunosuppressant effects, particularly B-cell targeted therapies including but not limited to ocrelizumab, ofatumumab, or obinutuzumab. Some authorities advise against their concomitant use.

Drug and food interactions

Major

pirtobrutinib food

Applies to: Jaypirca (pirtobrutinib)

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with pirtobrutinib as they may increase the blood levels of pirtobrutinib. This may increase the risk of side effects such as infection, bruising, bleeding, fatigue, muscle pain, diarrhea, swelling, and difficulty breathing. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer